Page last updated: 2024-08-21

2-piperidone and Liver Steatosis

2-piperidone has been researched along with Liver Steatosis in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Baik, SH; Choi, DS; Choi, KM; Hong, HC; Hwang, HJ; Jung, TW; Kim, BH; Kim, NH; Kim, SG; Seo, JA; Yoo, HJ1
Choi, SH; Lee, CK; Lee, IK; Leem, J; Park, KG; Park, S1

Other Studies

2 other study(ies) available for 2-piperidone and Liver Steatosis

ArticleYear
A dipeptidyl peptidase-IV inhibitor improves hepatic steatosis and insulin resistance by AMPK-dependent and JNK-dependent inhibition of LECT2 expression.
    Biochemical pharmacology, 2015, Nov-01, Volume: 98, Issue:1

    Topics: AMP-Activated Protein Kinases; Animals; Dietary Fats; Dipeptidyl-Peptidase IV Inhibitors; Fatty Liver; Hep G2 Cells; Humans; Insulin Resistance; Intercellular Signaling Peptides and Proteins; MAP Kinase Kinase 4; Mice; Mice, Inbred C57BL; Piperidones; Pyrimidines

2015
Gemigliptin ameliorates Western-diet-induced metabolic syndrome in mice.
    Canadian journal of physiology and pharmacology, 2017, Volume: 95, Issue:2

    Topics: Adipocytes; Animals; Diet, Western; Fatty Liver; Fibrosis; Hypercholesterolemia; Hypertrophy; Inflammation; Insulin Resistance; Liver; Male; Metabolic Syndrome; Mice; Piperidones; Pyrimidines; Subcutaneous Fat; Uncoupling Protein 1; Weight Gain

2017